Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP043
MIFTS: 50

Hyperandrogenism

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hyperandrogenism

About this section

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 12 76 55 44 15 73
Hyperandrogenization Syndrome 12

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11613
MeSH 44 D017588
UMLS 73 C0206081
Sources

Summaries for Hyperandrogenism

About this section
MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to cortisone reductase deficiency and acanthosis nigricans. An important gene associated with Hyperandrogenism is WNT4 (Wnt Family Member 4), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Hyperandrogenism, also known as androgen excess, is a medical condition characterized by excessive... more...

Sources

Related Diseases for Hyperandrogenism

About this section

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 cortisone reductase deficiency 31.5 CYP17A1 CYP21A2 HSD11B1 POMC
2 acanthosis nigricans 30.6 IGF1 INS INSR PRL SHBG
3 polycystic ovary syndrome 30.4 CYP17A1 CYP19A1 CYP21A2 GNRH1 HSD3B2 IGF1
4 3-beta-hydroxysteroid dehydrogenase deficiency 30.4 CYP21A2 HSD3B2
5 hyperinsulinism 30.3 IGF1 IGFBP1 INS INSR SHBG
6 leydig cell tumor 30.1 CYP17A1 CYP19A1 CYP21A2
7 diabetes mellitus 30.0 IGF1 IGFBP1 INS INSR SHBG
8 amenorrhea 30.0 GNRH1 POMC PRL SHBG WNT4
9 central precocious puberty 30.0 GNRH1 IGF1
10 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 29.9 CYP21A2 POMC
11 precocious puberty 29.9 CYP19A1 CYP21A2 GNRH1
12 androgenic alopecia 29.9 CYP19A1 PRL SHBG
13 anovulation 29.9 CYP19A1 GNRH1 IGF1 INS PRL SHBG
14 adenoma 29.9 CYP21A2 IGF1 POMC PRL
15 alopecia, androgenetic, 1 29.9 CYP19A1 CYP21A2 SHBG
16 hyperthyroidism 29.9 INS PRL SHBG
17 lipoid congenital adrenal hyperplasia 29.8 CYP17A1 CYP19A1 CYP21A2 HSD3B2 POMC
18 hyperglycemia 29.8 IGF1 INS INSR
19 adrenal adenoma 29.7 CYP17A1 CYP21A2 HSD11B1 POMC
20 conn's syndrome 29.7 CYP17A1 CYP21A2 POMC PRL
21 adrenal cortical adenoma 29.7 CYP17A1 CYP21A2 POMC
22 infertility 29.6 CYP19A1 GNRH1 PRL
23 hyperprolactinemia 29.6 GNRH1 IGF1 POMC PRL SHBG
24 insulin-like growth factor i 29.6 IGF1 IGFBP1 INS INSR PRL SHBG
25 bipolar disorder 29.4 IGF1 IGFBP1 PRL SHBG
26 glucose intolerance 29.4 IGF1 IGFBP1 INS INSR SHBG
27 acromegaly 29.3 IGF1 IGFBP1 INS POMC PRL
28 ovarian disease 29.2 CYP19A1 GNRH1 IGF1 IGFBP1 INS PRL
29 endometrial cancer 29.1 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
30 mullerian aplasia and hyperandrogenism 12.5
31 hyperandrogenism due to cortisone reductase deficiency 12.0
32 hair-an syndrome 12.0
33 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 11.7
34 ovarian stromal hyperthecosis 11.3
35 cortisone reductase deficiency 1 11.1
36 cortisone reductase deficiency 2 11.1
37 mayer-rokitansky-kuster-hauser syndrome 11.0
38 diabetes mellitus, insulin-resistant, with acanthosis nigricans 11.0
39 brachyolmia type 4 with mild epiphyseal and metaphyseal changes 11.0
40 testotoxicosis 11.0
41 polycystic ovary syndrome 1 10.3
42 noma 10.2 INS POMC
43 body mass index quantitative trait locus 1 10.2
44 secondary adrenal insufficiency 10.2 IGF1 INS
45 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.2 HSD11B1 INS
46 scleredema adultorum 10.2 INS POMC
47 acute adrenal insufficiency 10.2 CYP21A2 POMC
48 postmenopausal atrophic vaginitis 10.2 POMC SHBG
49 galactorrhea 10.2 IGF1 PRL
50 pancreatic endocrine carcinoma 10.2 INS POMC

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism
Sources

Symptoms & Phenotypes for Hyperandrogenism

About this section

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.7 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.7 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 CYP21A2 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.7 INSR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.7 IGF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.7 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.7 INSR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.7 CYP21A2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.7 SHBG
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.7 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.7 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.7 CYP21A2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.7 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.7 CYP21A2 IGF1 INSR SHBG
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.7 IGF1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.7 INSR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.7 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.7 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.7 IGF1

MGI Mouse Phenotypes related to Hyperandrogenism:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CYP17A1 CYP19A1 HSD11B1 IGF1 IGFBP1 INS
2 endocrine/exocrine gland MP:0005379 10.11 CYP19A1 GNRH1 HSD11B1 IGF1 INS INSR
3 growth/size/body region MP:0005378 10.09 CYP17A1 CYP19A1 GNRH1 HSD11B1 IGF1 INS
4 immune system MP:0005387 10.07 CYP19A1 GNRH1 HSD11B1 IGF1 IGFBP1 INS
5 adipose tissue MP:0005375 10.04 CYP17A1 CYP19A1 HSD11B1 IGF1 INS INSR
6 hematopoietic system MP:0005397 10.01 CYP19A1 GNRH1 HSD11B1 IGF1 INS INSR
7 integument MP:0010771 9.92 CYP19A1 GNRH1 HSD11B1 IGF1 INS POMC
8 liver/biliary system MP:0005370 9.86 CYP19A1 GNRH1 HSD11B1 IGFBP1 INS INSR
9 nervous system MP:0003631 9.81 CYP19A1 GNRH1 HSD11B1 IGF1 INS INSR
10 renal/urinary system MP:0005367 9.56 CYP17A1 CYP19A1 GNRH1 IGF1 INS INSR
11 reproductive system MP:0005389 9.23 CYP17A1 CYP19A1 GNRH1 IGF1 INS INSR
Sources

Drugs & Therapeutics for Hyperandrogenism

About this section

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
3
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
4
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
5 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 979-32-8
6
Drospirenone Approved Phase 4 67392-87-4 68873
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
9
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
10
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
13
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
14
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
15
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
18
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
19
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3 67-97-0 5280795 6221
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 1406-16-2
21
Enclomiphene Investigational Phase 4,Phase 3,Phase 2 15690-57-0
22 Estradiol 3-benzoate Phase 4,Phase 2,Not Applicable
23 Estradiol 17 beta-cypionate Phase 4,Phase 2,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Contraceptive Agents Phase 4,Phase 2,Not Applicable
26 Contraceptive Agents, Male Phase 4,Not Applicable
27 Estrogens Phase 4,Phase 3,Phase 2,Not Applicable
28 Androgen Antagonists Phase 4,Phase 2,Not Applicable
29
Cyproterone Phase 4,Not Applicable 2098-66-0 5284537
30 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
34 Mineralocorticoids Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Contraceptives, Oral Phase 4,Phase 2,Not Applicable
36 Contraceptives, Oral, Combined Phase 4,Phase 2,Not Applicable
37 Antioxidants Phase 4,Not Applicable
38 Cyproterone acetate, ethinyl estradiol drug combination Phase 4,Not Applicable
39 diuretics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
40 Drospirenone and ethinyl estradiol combination Phase 4
41 Natriuretic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Hemostatics Phase 4
43 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
44 Protective Agents Phase 4,Phase 3,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Not Applicable
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1,Not Applicable
48 Lipid Regulating Agents Phase 4,Not Applicable
49 Anticholesteremic Agents Phase 4,Not Applicable
50 Antineoplastic Agents, Phytogenic Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 134)
# Name Status NCT ID Phase Drugs
1 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
4 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
5 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
6 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
7 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
8 Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. Completed NCT01896492 Phase 4 NAC
9 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
10 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Completed NCT01721915 Phase 4 Vitamin D supplementation;Placebo
11 The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
12 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
13 Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
14 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
15 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
16 Research of Exenatide for Overweight/Obese PCOS Patients With IGR Recruiting NCT03352869 Phase 4 Exenatide;Metformin
17 Research of Intensive Metabolic Intervention Before Pregnancy in PCOS Not yet recruiting NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
18 Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study Unknown status NCT02133755 Phase 3 Bromocriptine
19 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
20 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
21 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3 Metformin
22 The Adrenal Contribution to Androgen Production in Girls During Puberty Completed NCT01062568 Phase 3 Adrenocorticotropin;Dexamethasone
23 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3 recombinant human chorionic gonadotropin
24 Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Completed NCT01961336 Phase 3 Testosterone
25 Obesity in Children and Adolescents: Associated Risks and Early Intervention Completed NCT01677923 Phase 3 Metformin
26 Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis Completed NCT02022007 Phase 3 Metformin XR;Saxagliptin;Saxagliptin-Metformin XR
27 The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS) Completed NCT02328404 Phase 3 50,000 IU vitamin D3;Placebo
28 Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. Recruiting NCT03334682 Phase 3 spironolactone;Doxycycline
29 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
30 Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Recruiting NCT03480022 Phase 3 Liraglutide Pen Injector [Saxenda];Placebo Liraglutide Pen Injector
31 DAPA, EQW, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) Recruiting NCT02635386 Phase 3 Exenatide once weekly (EQW );Dapagliflozin (DAPA);EQW plus DAPA;Dapagliflozin plus Glucophage (MET ER);Phentermine /Topiramate (PHEN/ TRP) ER
32 Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome Unknown status NCT02644304 Phase 2 Clomiphene citrate;Cabergoline
33 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2 leuprolide;Ethinyl estradiol/norethindrone
34 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women Completed NCT00704912 Phase 2 Orlistat/Meal Replacement/Lifestyle Modification;Loestrin 1/20;Combination of treatments
35 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
36 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2 Hydrocortisone (Solucortef)
37 Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients Completed NCT02562664 Phase 2 CC;Placebo tablets;Metformin
38 Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome Completed NCT03152591 Phase 2 LIK066;Placebo
39 Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism Recruiting NCT03757923 Phase 1, Phase 2 TAB METFORMIN;TAB PIOGLITAZONE
40 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
41 Acupuncture or Metformin for Insulin Resistance in Women With PCOS Recruiting NCT02647827 Phase 2 Metformin
42 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Recruiting NCT03229408 Phase 2 Salsalate
43 Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant Enrolling by invitation NCT02523898 Phase 2 metformine;placebo;clomiphene citrate
44 Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome Completed NCT01457209 Phase 1
45 Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Recruiting NCT01428089 Phase 1 Progesterone;Placebo
46 Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women Recruiting NCT02244567 Phase 1 Metformin 850 mg twice daily for 3 months
47 Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006) Terminated NCT01602679 Phase 1 oral micronized progesterone suspension;Placebo
48 Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Terminated NCT01489319 Phase 1 Salsalate;Salsalate
49 Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425 Not Applicable
50 Meal Timing on Glucose and Hyperandrogenism in PCOS Women Unknown status NCT01711476 Not Applicable

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Sources

Genetic Tests for Hyperandrogenism

About this section
Sources

Anatomical Context for Hyperandrogenism

About this section

MalaCards organs/tissues related to Hyperandrogenism:

41
Ovary, Liver, Bone, Endothelial, Heart, Testes, Prostate
Sources

Publications for Hyperandrogenism

About this section

Articles related to Hyperandrogenism:

(show top 50) (show all 579)
# Title Authors Year
1
Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. ( 29719598 )
2018
2
Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. ( 29068242 )
2018
3
Hyperandrogenism Enhances Muscle Strength After Progressive Resistance Training, Independent of Body Composition, in Women With Polycystic Ovary Syndrome. ( 29927897 )
2018
4
Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. ( 29376451 )
2018
5
Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). ( 29500679 )
2018
6
Gut Microbial Diversity in Women with Polycystic Ovary Syndrome Correlates with Hyperandrogenism. ( 29370410 )
2018
7
Hyperandrogenism controversy in elite women's sport: an examination and critique of recent evidence. ( 29351951 )
2018
8
C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. ( 29739821 )
2018
9
Progesterone Suppression of Luteinizing Hormone Pulse Frequency in Adolescent Girls With Hyperandrogenism: Effects of Metformin. ( 29095983 )
2018
10
An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism: A case report. ( 29517680 )
2018
11
Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. ( 29273198 )
2018
12
Hyperandrogenism Induces Histo-Architectural Changes in the Rat Uterus. ( 29929445 )
2018
13
The DNA methylation profile of oocytes in mice with hyperinsulinaemia and hyperandrogenism as detected by single-cell level whole genome bisulphite sequencing (SC-WGBS) technology. ( 29929576 )
2018
14
Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. ( 29457756 )
2018
15
Effect of exposure to second-hand smoke from husbands on biochemical hyperandrogenism, metabolic syndrome and conception rates in women with polycystic ovary syndrome undergoing ovulation induction. ( 29471520 )
2018
16
Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: possible role of ovarian wedge resection. ( 29298536 )
2018
17
A question of 'fairness': Why ethics should factor in the Court of Arbitration for Sport's decision on the IAAF Hyperandrogenism Regulations. ( 29643090 )
2018
18
Adipose Tissue is a Potential Source of Hyperandrogenism in Obese Female Rats. ( 29901265 )
2018
19
Salivary testosterone may not serve as a screening test in the diagnosis of biochemical hyperandrogenism. ( 29517119 )
2018
20
Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). ( 29991979 )
2018
21
Florid hyperandrogenism due to a benign adrenocortical adenoma. ( 30061126 )
2018
22
Identification of microRNAs and genes associated with hyperandrogenism in the follicular fluid of women with polycystic ovary syndrome. ( 29193229 )
2018
23
Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. ( 29992612 )
2018
24
Diagnostic Dilemma in Two Cases of Hyperandrogenism. ( 30050702 )
2018
25
Diagnostic Thresholds for Androgen-Producing Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry. ( 30068692 )
2018
26
Are Psychosocial Consequences of Obesity and Hyperandrogenism Present in Adolescent Girls with Polycystic Ovary Syndrome? ( 30147723 )
2018
27
Profiles for long non-coding RNAs in ovarian granulosa cells from women with PCOS with or without hyperandrogenism. ( 30224242 )
2018
28
Hyperandrogenism in Female Athletes. ( 30285117 )
2018
29
Ovarian tumors secreting androgens: an infrequent cause of hyperandrogenism. ( 30291701 )
2018
30
Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements. ( 30350882 )
2018
31
Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women. ( 30481153 )
2018
32
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. ( 29161258 )
2017
33
The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse. ( 28961951 )
2017
34
Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS. ( 28912337 )
2017
35
Hyperandrogenism in a postmenopausal woman: a rare case of ectopic adrenal cortical gland. ( 28102088 )
2017
36
Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate. ( 28540758 )
2017
37
Value of selective venous catheterization in the diagnosis of hyperandrogenism. ( 29100622 )
2017
38
The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. ( 28572510 )
2017
39
ADT-G as a promising biomarker for peripheral hyperandrogenism in adult female acne. ( 29497466 )
2017
40
Correction to: Fulghesu etA al., Very low dose of flutamide in the treatment of hyperandrogenism. ( 29171313 )
2017
41
Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. ( 28593921 )
2017
42
Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China. ( 28413474 )
2017
43
The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. ( 28620353 )
2017
44
Prevalence of Prediabetes Risk in Offspring Born to Mothers with Hyperandrogenism. ( 28111236 )
2017
45
Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. ( 28575537 )
2017
46
The prevalence of non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Russian women with hyperandrogenism. ( 28669219 )
2017
47
An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients. ( 28125989 )
2017
48
A peel-off facial mask comprising myoinositol and trehalose-loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy. ( 28342238 )
2017
49
Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype? ( 28649885 )
2017
50
Transient hyperandrogenism in 2 preterm twins with exposure to antiretrovirals. ( 28864089 )
2017
Sources

Variations for Hyperandrogenism

About this section
Sources

Expression for Hyperandrogenism

About this section
Search GEO for disease gene expression data for Hyperandrogenism.
Sources

Pathways for Hyperandrogenism

About this section

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.76 IGF1 INS INSR PRL WNT4
2
Aldosterone synthesis and secretion 37
Show member pathways
 12.53 CYP17A1 CYP21A2 HSD3B2 INS POMC
3
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.24 IGF1 INS INSR WNT4
4
Glucose / Energy Metabolism 4
12.21 CYP17A1 CYP19A1 IGFBP1 INS INSR
5
Cushing syndrome 37
Show member pathways
 12.06 CYP17A1 CYP21A2 HSD3B2 POMC WNT4
6
Longevity regulating pathway 37
Show member pathways
 11.93 IGF1 INS INSR
7
FoxO signaling pathway 37
Show member pathways
 11.86 IGF1 INS INSR
8
HIF-1 signaling pathway 37
11.69 IGF1 INS INSR
9
Corticotropin-releasing hormone signaling pathway 1
11.64 CYP21A2 HSD3B2 POMC
10
Metabolism of steroid hormones 66
Show member pathways
 11.38 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2 POMC
11
Steroid hormone biosynthesis 37
Show member pathways
 11.37 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
12
Androstenedione and testosterone biosynthesis and metabolism p.1 22
Show member pathways
 11.34 CYP17A1 CYP19A1 HSD3B2
13
Signaling events mediated by PTP1B 1
11.28 INS INSR PRL
14
Aldosterone-regulated sodium reabsorption 37
11.11 IGF1 INS INSR
15
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.89 IGF1 IGFBP1
16
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.88 CYP17A1 CYP21A2
17
Nongenotropic Androgen signaling 1
10.79 GNRH1 SHBG
18
Ovarian steroidogenesis 37
10.79 CYP17A1 CYP19A1 HSD3B2 IGF1 INS INSR
Sources

GO Terms for Hyperandrogenism

About this section

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.65 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
2 extracellular space GO:0005615 9.5 GNRH1 IGF1 IGFBP1 INS POMC PRL
3 extracellular region GO:0005576 9.23 GNRH1 IGF1 IGFBP1 INS POMC PRL
4 endosome lumen GO:0031904 9.16 INS PRL

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.97 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
2 cellular protein metabolic process GO:0044267 9.8 IGF1 IGFBP1 INS PRL
3 positive regulation of MAPK cascade GO:0043410 9.77 IGF1 INS INSR
4 steroid metabolic process GO:0008202 9.77 CYP17A1 CYP21A2 HSD11B1
5 glucose homeostasis GO:0042593 9.76 INS INSR POMC
6 insulin receptor signaling pathway GO:0008286 9.7 IGFBP1 INS INSR
7 activation of protein kinase B activity GO:0032148 9.63 IGF1 INS INSR
8 regulation of signaling receptor activity GO:0010469 9.63 GNRH1 IGF1 INS POMC PRL WNT4
9 female gonad development GO:0008585 9.62 CYP19A1 WNT4
10 sex differentiation GO:0007548 9.61 CYP17A1 WNT4
11 adrenal gland development GO:0030325 9.61 INSR WNT4
12 positive regulation of glucose import GO:0046326 9.61 IGF1 INS INSR
13 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS INSR
14 male sex determination GO:0030238 9.57 GNRH1 INSR
15 androgen biosynthetic process GO:0006702 9.56 CYP17A1 HSD3B2
16 neuron projection maintenance GO:1990535 9.55 INS INSR
17 ovulation cycle GO:0042698 9.54 GNRH1 PRL
18 sterol metabolic process GO:0016125 9.54 CYP17A1 CYP19A1 CYP21A2
19 positive regulation of respiratory burst GO:0060267 9.51 INS INSR
20 positive regulation of glycolytic process GO:0045821 9.5 IGF1 INS INSR
21 mineralocorticoid biosynthetic process GO:0006705 9.48 CYP21A2 HSD3B2
22 positive regulation of glycogen biosynthetic process GO:0045725 9.43 IGF1 INS INSR
23 steroid biosynthetic process GO:0006694 9.26 CYP17A1 CYP19A1 CYP21A2 HSD3B2
24 glucocorticoid biosynthetic process GO:0006704 8.92 CYP17A1 CYP21A2 HSD11B1 HSD3B2

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.77 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
2 heme binding GO:0020037 9.63 CYP17A1 CYP19A1 CYP21A2
3 iron ion binding GO:0005506 9.61 CYP17A1 CYP19A1 CYP21A2
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.5 CYP17A1 CYP19A1 CYP21A2
5 insulin receptor binding GO:0005158 9.48 IGF1 INS
6 insulin-like growth factor I binding GO:0031994 9.4 IGFBP1 INSR
7 steroid binding GO:0005496 9.33 CYP21A2 HSD11B1 SHBG
8 insulin-like growth factor II binding GO:0031995 9.26 IGFBP1 INSR
9 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS INSR
10 hormone activity GO:0005179 9.02 GNRH1 IGF1 INS POMC PRL
Sources

Sources for Hyperandrogenism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....